Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial
Phase 3negativedel-desiranNegative
AI Analysis
Summary
Novartis's del-desiran, acquired with Avidity, failed the Phase III HARBOR trial by missing its primary endpoint of statistically significant improvement in video Hand Opening Time versus placebo at week 54 in a neuromuscular indication.
Clinical Trial Data
Outcome Details
Failed to meet primary endpoint of statistically significant improvement vs. placebo in video Hand Opening Time (vHOT) through week 54
Importance:8/10
Sentiment:
-0.90
Phase_3_failureneuromuscularmyotoniaprimary_endpoint_missstock_decline
Read the original article
Published by GEN - Genetic Engineering & Biotech News on September 9, 2026 1:03 AM